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136Factors that inﬂuence perforator thrombosis and
predict healing with perforator sclerotherapy for
venous ulceration without axial reﬂux
Misaki M. Kiguchi, MD, MBA,a Eric S. Hager, MD,a Daniel G. Winger, MS,b Stanley A. Hirsch, MD,a
Rabih A. Chaer, MD,a and Ellen D. Dillavou, MD,a Pittsburgh, Pa
Objective: Reﬂuxing perforators contribute to venous ulceration. We sought to describe patient characteristics and
procedural factors that (1) impact rates of incompetent perforator vein (IPV) thrombosis with ultrasound-guided
sclerotherapy (UGS) and (2) impact the healing of venous ulcers (CEAP 6) without axial reﬂux.
Methods: A retrospective review of UGS of IPV injections from January 2010 to November 2012 identiﬁed 73 treated
venous ulcers in 62 patients. Patients had no other superﬁcial or axial reﬂux and were treated with standard wound care
and compression. Ultrasound imaging was used to screen for reﬂuxing perforators near ulcer(s). These were injected with
sodium tetradecyl sulfate or polidocanol foam and assessed for thrombosis at 2 weeks. Demographic data, comorbidities,
treatment details, and outcomes were analyzed. Univariate and multivariable modeling was performed to determine
covariates predicting IPV thrombosis and ulcer healing.
Results: There were 62 patients (55% male; average age, 57.1 years) with active ulcers for an average of 28 months with
compression therapy before perforator treatment, and 36% had a history of deep venous thrombosis and 30% had deep
venous reﬂux. At a mean follow-up of 30.2 months, ulcers healed in 32 patients (52%) and did not heal in 30 patients
(48%). Ulcers were treated with 189 injections, with an average thrombosis rate of 54%. Of 73 ulcers, 43 ulcers (59%)
healed, and 30 (41%) did not heal. The IPV thrombosis rate was 69% in patients whose ulcers healed vs 38% in patients
whose ulcers did not heal (P < .001). Multivariate models demonstrated male gender (P[ .03) and warfarin use (P[ .01)
negatively predicted thrombosis of IPVs. A multivariate model for ulcer healing found complete IPV thrombosis was a
positive predictor (P [ .02), whereas a large initial ulcer area was a negative predictor (P [ .08). Increased age was
associated with fewer ulcer recurrences (P[ .05). Predictors of increased ulcer recurrences were hypertension (P[ .04)
and increased follow-up time (P [ .02). Calf vein thrombosis occurred after 3% (six of 189) of injections.
Conclusions: Thrombosis of IPVs with UGS increases venous ulcer healing in a difﬁcult patient population. Complete
closure of all IPVs in an ulcerated limb was the only predictor of ulcer healing. Men and patients taking warfarin have
decreased rates of IPV thrombosis with UGS. (J Vasc Surg 2014;59:1368-76.)Incompetent perforator veins (IPVs) have long been
associated with venous disease and ulceration. Perforator
veins in and around the ankles are particularly vulnerable
to incompetence, and venous hypertension in this area cre-
ates edema, skin discoloration, and ulceration.1 Compres-
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8and reﬂux. However, even in compliant patients, there is a
high chance of recurrent ulceration and symptoms due to
failure to correct the underlying pathology.2,3 Milic et al4
found a 24% recurrence rate at 1 year in patients compliant
with compression vs a 53% recurrence rate in those without
(P < .05). This study buttresses the plethora of literature
demonstrating that compression therapy decreases but
does not prevent ulcer recurrence.5-8 Owing to poor ulcer
healing with compression alone, other treatment strategies
aim to treat the mechanisms of venous incompetence and
reduce venous hypertension.
Although open perforator ligation (Linton procedure)9
and subfascial endoscopic perforator surgery10,11 improve
ulcer healing,12,13 they are both associated with high
morbidity. A paradigm shift toward ablative therapy has
occurred, with increased technical success and fewer
complications.14
Ultrasound-guided sclerotherapy (UGS) has recently
been advocated to treat IPV associated with venous ulcers.
Masuda et al15 demonstrated good technical results with
low complication rates using UGS for treatment of IPV.
Although factors affecting overall venous ulcer healing
and recurrence have been previously described,2,5,16-19
published studies of speciﬁc modalities so far have focused
primarily on improved subjective venous clinical scores
Fig. Study design.
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randomized comparison between UGS and direct catheter-
based ablation techniques, uncertainty persists regarding
the best type of IPV treatment. In addition, limited data
are available on the predictors of successful UGS of IPV
and its impact on ulcer healing. The purpose of this report
is to describe patient characteristics and periprocedural fac-
tors that affect rates of IPV closure using UGS and how
this affects healing of venous ulcers.
METHODS
Institutional Review Board approval was obtained for
prospective and retrospective reviews of a clinical database
of patients with active venous ulcer(s) treated at the Uni-
versity of Pittsburgh Medical Center. Patients were identi-
ﬁed from a prospectively maintained database of patients
with venous ulcers and also through a query for
ultrasound-guided injections in our electronic medical re-
cord system. Those with venous ulcers (CEAP 6, active ul-
cer)20 who underwent UGS of IPV(s) from January 2010
to November 2012 were included in the analysis. All pa-
tients received standard of care compression and wound
therapy throughout the study treatment period (Fig).
Initial evaluation. Patients underwent a complete his-
tory and physical and comprehensive venous duplex ultra-
sound assessment of surface varicosities as well as the
deep, superﬁcial, and perforator veins. All veins were
assessed for dilation, reﬂux, presence of acute or chronic
thrombus, and geographic relationship to the ulcer. Reﬂux-
ing perforators of at least 3.5 mm in diameter and immedi-
ately next to the ulcer or directly feeding varicosities in the
vicinity of the ulcer were considered pathologic. All pa-
tients were scored with CEAP classiﬁcation.20 Patients
were assessed in this manner at the time of the initial pre-
sentation to the practice, but due to variations in practice
patterns or patient preference, or both, patients may not
have had treatment of perforator disease until it was
demonstrated that compressive therapy alone was not
successful in healing venous wounds.
Ulcer management. All patients underwent compres-
sive therapy, usually with Unna boot(s) or short stretch
bandages. Superﬁcial debridement was performed on
venous ulcers at the discretion of the provider. Patients
with saphenous vein reﬂux of >1 second and a diameter
$5 mm were treated with radiofrequency or laser ablation.
Patients were included in the study if they had persistent ul-
ceration and reﬂuxing perforators >3.5 mm after saphe-
nous ablation.
UGS technique. Before the injection, the location(s)
of the perforator(s) were described in the ultrasound
report, and this detailed documentation was used as a refer-
ence for follow-up comparison. UGS injections were per-
formed by board-certiﬁed vascular surgeons with the aid of
a registered vascular technologist using a Logiq 9 or E9
machine (General Electric Medical Systems, Milwaukee,
Wisc). Foam was prepared using the Tessari method with a
4:1 air/sclerosant mixture.21 Before May 2010, 1% sodium
tetradecyl sulfate (STS) was used. After May 2010, 1% or3% polidocanol sclerosing agent was used at the discretion
of the provider.
Under direct ultrasound visualization, a 23-gauge
needle was inserted into the varicosities fed by the IPV.
Foam was prepared and immediately instilled into the can-
nulated vein under direct ultrasound visualization. The skin
surrounding the ulcer and injection site was massaged to
move the foam into the perforator as well as into adjacent
varicosities or venous plexi. When foam sclerosant ﬁlled the
IPV, pressure was held at the junction of the IPV and the
deep vein for at least 2 minutes with an ultrasound probe.
The injected perforating vein and surrounding varicosities
were subsequently imaged to ensure sclerosis. A goal
amount of #10 mL of foam was used per injection session
to limit the amount of air instilled. Patients with multiple
perforators could have several injections sessions scheduled
to limit foam. After the injection, deep veins were imaged
to ensure that they were clear of foam and compressible.
Patients were supine during the injection, compression
was applied, and they were allowed to ambulate immedi-
ately after. Compression therapy was applied immediately
after the procedure and left in place for at least 24 hours
before the patient’s standard wound care and compression
therapy were resumed. For patients with Unna boots, the
dressing was reapplied immediately after the UGS proce-
dure. Patients receiving anticoagulation did not have this
therapy held during the injections. All patients underwent
an UGS injection in at least one IPV during the study
period, and some had multiple injections in an IPV or mul-
tiple IPVs.
Follow-up. Patients with continuous Unna boot
compression therapy were seen weekly after treatment ac-
cording to the standard of clinical care. Patients receiving
other wound care and compression therapies were seen at
2, 4, and 6 weeks and then every 6 weeks thereafter. At
2 weeks, a duplex ultrasound assessment by the same tech-
nologist used during the injection was performed to eval-
uate for thrombosis of the injected perforator, rule out
deep vein thrombosis (DVT), and assess for new IPVs.
Table I. Demographic variables in patients undergoing
ultrasound-guided sclerotherapy (UGS) of incompetent
perforator veins (IPV)
Variable Result (N ¼ 62)
Male, % 55
Mean age (range), years 57.1 (22-85)
BMI >30 kg/m2, % 53
Deep venous reﬂux, % 31
Previous DVT, % 36
Smoking history, current smoking, % 53
Diabetes mellitus, % 13
Hypercoagulable state, % 5
Hyperlipidemia, % 47
Hypertension, % 71
Chronic obstructive pulmonary disease, % 5
Taking medication
Aspirin, % 36
Coumadin,a % 21
Aspirin and Coumadin, % 8
Diuretic, % 39
BMI, Body mass index; DVT, deep vein thrombosis.
aBristol-Myers Squibb, Princeton, NJ.
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recanalization of treated IPVs was performed for a decline
or stagnation in the progress of wound healing or for other
clinical indications.
Venous ulcer(s) were measured at each visit and
recorded in a ﬂow sheet imbedded in the electronic medi-
cal record. The area of the ulcer was calculated to deter-
mine the rate of healing. The dates of complete ulcer
healing and last known follow-up were recorded for each
patient. After complete ulcer healing, patients were told
to continue compression and return for any new symp-
toms. Phone contact was initiated when patients were ab-
sent from the clinic for $6 months to ensure that no
new ulcers had developed.
Outcomes and deﬁnitions. Primary outcomes
included (1) incidence of thrombosis after UGSs of
IPV(s), (2) success of complete closure of all IPVs in an ul-
cerated limb, and (3) healing status, a binary outcome
deﬁned by the presence or absence of a venous ulcer at last
known follow-up. The secondary continuous outcome
focused on ulcer recurrence, which was identiﬁed as ulcer
healing and then opening in the same anatomic area at any
point during the study period.
Statistical analysis. All statistical analysis was conduct-
ed by the Clinical and Translational Science Institute at the
University of Pittsburgh Medical Center using R 2.15.1
software (R Foundation for Statistical Computing, Vienna,
Austria) and Stata 11.2 software (StataCorp LP, College
Station, Tex).
Analyses were initiated by running exploratory univar-
iate models using clinically relevant variables. For each pri-
mary and secondary outcome, each demographic,
comorbidity, and procedural predictor was entered by itself
in a linear (for continuous outcomes) or binomial (for
dichotomous outcomes) mixed-effects model, which ac-
counts for the repeated measures of multiple ulcers in indi-
vidual patients. The coefﬁcient (continuous outcomes) or
odds ratio (OR; dichotomous outcomes) was calculated
with the P value of < .05 considered signiﬁcant. Within
each outcome, any variable that achieved P < .20 signiﬁ-
cance in univariate modeling was selected as a candidate
for multivariable modeling. Multivariable modeling was
conducted as a backward stepwise regression, excluding
the least signiﬁcant variable until only variables with
P < .10 remained. Procedural predictors with partial collin-
earity with the outcome were not tested or included.
Linear or binomial mixed-effects models were used to ac-
count for multiple ulcers from the same patient by means
of incorporating a random effects term and robust standard
errors.
RESULTS
Analysis of UGS injections of IPVs from January 2010
to November 2012 identiﬁed 73 venous ulcers in 62 pa-
tients who had compression and standard wound care for
an average of 28 months before perforator ablation.
Follow-up duplex ultrasound imaging was performed in
98% of patients. At the last follow-up visit, ulcers hadhealed in 32 of 62 patients (52%), whereas 30 patients
had at least 1 nonhealed ulcer (Table I). Of 73 ulcers, 43
ulcers healed (group H), whereas 30 ulcers recurred or
never healed (group NH), for a healing rate of 59% at
the last follow-up. Mean initial ulcer size was 3.56 cm2 in
group H vs 15.15 cm2 in group NH (P ¼ .10). Median
initial ulcer size was 1.61 cm2 in group H vs 4.40 cm2 in
group NH.
Perforator injection results. A total of 189 injections
were performed. An average of 10.2 mL foam was used per
session: 1% polidocanol used in 74% of injections, with 3%
polidocanol used in 86% of these. There were no differ-
ences in STS 1% vs 1% or 3% polidocanol injection throm-
bosis rates or complications. The overall IPV closure rate
was 54%. Thrombosis occurred in 69% of injections for
group H vs 38% of the injections for group NH (P <
.001). At the end of follow-up, 92% of group H ulcers
had closure of all IPV in the affected limb (complete
closure) vs 68% of group NH ulcers (P ¼ .02). The average
number of unsuccessful injections before the ﬁrst successful
injection was 0.28 for group H vs 0.52 for group NH (P ¼
.29). Group H ulcers averaged 2.3 injections per ulcer vs
3.1 in group NH (P ¼ .13).
After the ﬁrst UGS, 48 ulcers had thrombosed IPVs
and 25 ulcers had IPVs that failed to thrombose (66%
closure rate for ﬁrst injection). There were 116 subsequent
UGS treatments of IPVs, 52 (45%) of which were success-
ful (P ¼ .12 compared with initial injections). In group H,
36 of 54 subsequent injections (67%) were successful,
compared with group NH, where 16 of 62 subsequent in-
jections (26%) were successful (P < .001). Of healed ulcers,
23% required a single perforator injection.
Postprocedure DVTs were seen in 3% of injections (six
of 189) in six patients (10%), two in group H and four in
group NH (P ¼ .35). All were short-occlusion posterior
Table II. Univariate and multivariable binary logistic regression analysis to predict thrombosis of last ultrasound-guided
sclerotherapy (UGS) injections of incompetent perforator veins (IPVs)
Variable
Univariate Multivariable
OR (per unit) 95% CI P OR (per unit) 95% CI P
Male sex 0.61 0.13-2.75 .52
Age, years 0.98 0.93-1.03 .35
Maximum BMI, kg/m2 0.73 0.46-1.17 .20
Maximum BMI >30 kg/m2 0.27 0.05-1.36 .11
Maximum weight, kg 0.96 0.91-1.01 .16
Deep vein reﬂux 1.21 0.26-5.56 .80
Previous DVT 0.98 0.23-4.24 .98
Smoking history, current smoking 2.36 0.50-11.1 .28
Hyperlipidemia 0.36 0.09-1.45 .15
Hypertension 0.39 0.05-2.91 .36
Taking Coumadina 0.13 0.0003-55.6 .51
DVT after UGS of IPV 0.06 0.0003-13.5 .31
No. of UGS of IPV 0.65 0.48-0.87 .004 0.65 0.48-0.87 .004
Initial follow-up to last follow-up, days 1.0001 0.9995-1.00 .74
Initial ulcer area, cm2 1.02 0.95-1.08 .66
CI, Conﬁdence interval; BMI, body mass index; DVT, deep vein thrombosis; OR, odds ratio.
aBristol-Myers Squibb, Princeton, NJ.
Table III. Univariate and multivariable linear regression analysis to predict percentage of thrombosis of ultrasound-
guided sclerotherapy (UGS) injections of incompetent perforator veins (IPVs)
Variable
Univariate Multivariable
Net effect (per unit) 95% CI P Net effect (per unit) 95% CI P
Male sex 0.18 0.35 to 0.01 .04 0.21 0.37 to 0.02 .03
Age, years 0.003 0.009 to 0.004 .41
Maximum BMI, kg/m2 0.01 0.03 to 0.002 .01
Maximum BMI >30, kg/m2 0.19 0.36 to 0.03 .02
Maximum weight, kg 0.002 0.003 to 0.0005 .01
Deep vein reﬂux 0.04 0.23 to 0.14 .63
Previous DVT 0.08 0.26 to 0.09 .35
Smoking history, current smoking 0.10 0.07 to 0.27 .26
Hyperlipidemia 0.09 0.26 to 0.09 .33
Hypertension 0.10 0.29 to 0.09 .30
Taking Coumadina 0.18 0.36 to 0.005 .06 0.21 0.38 to 0.05 .01
DVT after UGS of IPV 0.22 0.50 to 0.07 .14 0.25 0.53 to 0.02 .06
Initial follow-up to last follow-up, days 0.00003 0.0001 to 0.00005 .46
Initial ulcer area, cm2 0.002 0.005 to 0.002 .34
CI, Conﬁdence interval; BMI, body mass index; DVT, deep vein thrombosis.
aBristol-Myers Squibb, Princeton, NJ.
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taking warfarin for various reasons and the remaining 66%
were prescribed 325 mg/d aspirin, with 100% recanaliza-
tion of their short-occlusion thromboses on follow-up
duplex ultrasound assessments. No other injection compli-
cations were seen.
Predictors of IPV thrombosis. Univariate analysis
revealed an increased number of UGS injections negatively
predicted successful thrombosis of IPVs (Tables II and
III). For every additional UGS injection, we expect to see a
35% decrease in the odds of an eventual successful
thrombosis of IPVs (OR, 0.65; 95% conﬁdence interval
[CI], 0.48-0.87; P ¼ .004).Increased weight (P ¼ .01), increased body mass index
(BMI; P ¼ .01), BMI >30 kg/m2 (P ¼ .02), and male
gender (P ¼ .04) all negatively predicted thrombosis after
UGS. Male gender highly correlated with increased BMI,
and thus, gender association may be a result of men with
increased BMI in our study population.
Multivariable modeling similarly demonstrated that
postprocedural DVT (P ¼ .06), male gender (P ¼ .03),
and warfarin use (P ¼ .01) negatively predicted IPV
thrombosis.
Predictors of ulcer healing and recurrence. Ulcer
healing was predicted by IPV thrombosis (Tables IV and
V). For each 10% increase in IPV thrombosis, we saw a 16%
Table IV. Univariate and multivariable binary logistic regression analysis to predict ultimate ulcer healing
Variable
Univariate Multivariable
OR (per unit) 95% CI P OR (per unit) 95% CI P
Male sex 0.64 0.25-1.64 .35
Age, years 0.98 0.95-1.02 .36
Maximum weight, kg 0.998 0.99-1.0 .63
Deep vein reﬂux 1.07 0.40-2.87 .89
Previous DVT 0.89 0.34-2.31 .81
Smoking history, current smoking 1.31 0.52-3.35 .58
Hyperlipidemia 0.75 0.29-1.92 .55
Hypertension 0.88 0.30-2.63 .83
Taking Coumadina 0.96 0.36-2.60 .95
DVT after UGS of IPV 0.32 0.05-1.86 .20
Last UGS IPV injection a success 4.50 1.23-16.5 .02 4.87 1.28-18.47 .02
No. of UGS of IPV 0.82 0.65-1.03 .10
Initial follow-up to last follow-up, days 1.0002 0.9996-1.0008 .46
% Success UGS of IPV 4.31 1.06-17.96 .04
Initial ulcer area, cm2 0.92 0.84-1.01 .10 0.92 0.83-1.01 .08
BMI, Body mass index; CI, conﬁdence interval; DVT, deep vein thrombosis; IPV, incompetent perforator veins; OR, odds ratio; UGS, ultrasound-guided
sclerotherapy.
aBristol-Myers Squibb, Princeton, NJ.
Table V. Univariate and multivariable linear regression analysis to predict ulcer recurrence
Variable
Univariate Multivariable
Net effect (per unit) 95% CI P Net effect (per unit) 95% CI P
Male gender 0.50 0.15 to 1.15 .13
Age, years 0.02 0.04 to 0.01 .14 0.02 0.34 to 0.0004 .05
Maximum weight, kg 0.003 0.003 to 0.008 .34
Deep vein reﬂux 0.45 0.25 to 1.16 .21
Previous DVT 0.04 0.73 to 0.65 .91
Smoking history, current smoking 0.34 0.31 to 1.002 .30
Diabetes mellitus 0.90 0.07 to 1.87 .07
Hyperlipidemia 0.002 0.67 to 0.66 .99
Hypertension 0.49 0.24 to 1.21 .19 0.78 0.01 to 1.54 .04
Taking Coumadina 0.37 0.35 to 1.07 .31
DVT after UGS of IPV 0.66 1.16 to 0.94 .84
Last UGS IPV injection a success 0.0003 0.78 to 0.78 .999
Initial follow-up to time to ﬁrst
UGS of IPV, days
0.0004 0.0001-0.001 .01
No. of UGS of IPV 0.05 0.09 to 0.18 .50
Initial follow-up to last follow-up, days 0.0004 0.0001-0.0006 .005 0.0003 0.00005 to 0.0006 .02
% Success of UGS IPV 0.58 1.47 to 0.30 .19
Initial ulcer area, cm2 0.004 0.02 to 0.009 .54
CI, Conﬁdence interval; DVT, deep vein thrombosis; IPV, incompetent perforator veins; UGS, ultrasound-guided sclerotherapy.
aBristol-Myers Squibb, Princeton, NJ.
JOURNAL OF VASCULAR SURGERY
1372 Kiguchi et al May 2014increase in the odds of healed venous ulcer status at the end
of follow-up (OR, 4.31; 95% CI, 1.04-17.95; P ¼ .04).
Patients with complete IPV closure (thrombosis of all
perforating veins in a limb) on the last UGS had a 3.5-times
greater chance of ulcer healing compared with failure
of complete closure (OR, 4.50; 95% CI, 1.23-16.51;
P ¼ .02).
Multivariable modeling demonstrated IPV complete
closure positively predicted ultimate ulcer healing (OR,
4.87; 95% CI, 1.28-18.5; P ¼ .02), whereas each increase
in cm2 initial ulcer area negatively predicted ultimate ulcer
healing (OR, 0.92; 95% CI, 0.83-1.0; P ¼ .08). Increasedage at the initial visit predicted fewer recurrences of ulcers
in the multivariable model, whereas increased follow-up
time and hypertension were seen with increased ulcer
recurrence.
Variables that negatively inﬂuenced ulcer healing on
univariate analysis included additional perforator injections
(OR, 0.82; 95% CI, 0.65-1.03; P ¼ .1) and increased initial
ulcer size (OR, 0.92; 95% CI, 0.84-1.01; P ¼ .1). Time
from the initial visit to the ﬁrst perforator injection
appeared to predict recurrence of ulcers. Each year of ulcer
existence before injection predicted 0.14 more recurrences
of ulceration (P ¼ .01). In addition, each additional year of
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 5 Kiguchi et al 1373follow-up after injection predicted 0.14 ulcer recurrences
(P ¼ .01).
Follow-up. Overall median follow-up with inter-
quartile range (IQR, 25th-75th percentile) was
33.5 months (IQR, 8.9-79.9 months), and median follow-
up for patients in various healing groups broke down as
healed ulcers, 12.2 months (IQR, 5.7-38.6 months);
recurrent ulcers that were healed at last follow-up,
94.7 months (IQR, 60.3-103.0 months); ulcers that
healed, recurred, and were open at last follow-up,
71.0 months (IQR, 33.6-93.9 months); and ulcers that
never healed, 18.1 months (IQR, 6.1-44.7 months). We
grouped the two recurrent ulcer groups in comparison with
ulcers that healed without recurrence or never healed in a
mixed-effects model, which demonstrated that total
follow-up time was strongly associated with recurrence.
Each additional year of follow-up was associated with a 56%
increase in chance of recurrence (P ¼ .001). Other factors
that were associated with ulcer recurrence were younger
patient age (P ¼ .05) and hypertension (P ¼ .04).
Because follow-up time strongly predicted recurrence,
healing status is likely inﬂuenced by how long the patients’
ulcers were monitored and reﬂects ﬂuidity in the healing of
this population. A multivariable logistic regression was run
on 62 ulcers in 62 patients, comparing never-healed ulcers
with those ulcers that healed and recurred in an effort to
ascertain if there were factors that appeared to prohibit ul-
cer healing at any time point. Predictors of increased ulcer
healing were closure of IPVs (P ¼ .04) and follow-up (P ¼
.09). If recurrent ulcers were analyzed separately from
healed ulcers, multivariable logistic regression analysis
revealed diuretic use (P ¼ .07), more UGS IPV injections
(P ¼ .08), and longer follow-up time (P ¼ .01) were asso-
ciated with recurrence.
DISCUSSION
Despite the proven efﬁcacy of compression ther-
apy,5,6,22-26 venous ulcers will not heal in a subset of
compression-treated patients despite strict compliance.
Correction of great saphenous vein reﬂux is associated
with signiﬁcant ulcer healing and decreases in ulcer recur-
rence.25 For ulcers that persist, minimally invasive elimina-
tion of pathologic IPVs near the ulcer increases healing
rates and may decrease recurrence, with few wound com-
plications and high rates of technical success.10,14,27 Pa-
tients with healed ulcers that were treated with IPV
ablation and continued to maintain compression therapy
had signiﬁcantly reduced recurrence rates compared with
compression alone.28 However, perforator ablation re-
quires instrumentation into or near an active ulcer, is a
more difﬁcult technique to master, and does not treat the
associated varicosities fed by an IPV.
Thermal ablation of perforators has a high overall tech-
nical closure rate (w80%-90%).29-31 Early results of sclero-
therapy by Guex32 showed a comparable 90% occlusion
rate after three or fewer sessions. Ultrasound-guided perfo-
rator injection is attractive because this therapy can be
delivered through a varicosity remote from the ulcer andthus decreases wound complications and procedural
discomfort. In addition, this therapy can be used to elimi-
nate multiple pathologic perforators and their associated
varicosities in one sitting. It is rapidly performed and is
technically straightforward. Unlike ablative techniques,
sclerotherapy is able to be performed virtually 100% of
the time. Many series of ablative perforator techniques
appear to report closure rates for perforators successfully
cannulated but not all attempts at cannulation and abla-
tion. In addition, UGS is much less expensive and could
potentially represent signiﬁcant savings to the health sys-
tem. Previous studies of UGS have demonstrated throm-
bosis rates after 3 months varying from 69% to 96%,
whereas follow-up studies at 1 to 2 years demonstrated
rates of 53% to 80% in great saphenous veins and varicose
veins.33 However, little work has been done to illustrate
the effect of UGS on ulcer healing when performed on pa-
tients without other treatable venous pathologies.
Our study population consisted of patients in whom
compression therapy had failed for more than 2 years
before treatment and who had no superﬁcial reﬂux. In
this very difﬁcult population, perforator thrombosis was
achieved in 54% of injections, demonstrating the
complexity and severity of venous disease as well as a major
drawback of this technique. Physiologic reasons for a
decrease in successful IPV thrombosis compared with axial
veins includes that IPVs are short high-ﬂow vessels, multi-
ple perforators may feed a network of varicosities, and
many patients (>30%) are receiving chronic anticoagula-
tion. Previous work has demonstrated decreased throm-
bosis after UGS in patients with ulcer.15 We found
warfarin use resulted in a 20% decrease in thrombosis.
Each ulcer averaged 2.67 injections. Repeated injec-
tions were performed for incomplete thrombosis after the
initial injection, recanalized perforators, and treatment of
new or additional perforators. Each additional injection
predicted 35% lower odds of the eventual total IPV throm-
bosis after UGS. This likely reﬂects two potentially overlap-
ping populations: patients with many perforators in the
ulcerated limb who required several sessions to safely treat
these veins and patients who had a lower rate of perforator
thrombosis. Regardless, both groups represent more severe
venous and perforator disease. We found that repeated
treatments had a success rate of 45%. Although this was
lower than the initial injection thrombosis rate of 66%
(P ¼ .12), ulcer healing increased with successful throm-
bosis of IPVs. Thus, we endorse continued perforator in-
jection or other methods of perforator ablation in the
face of initial failure until thrombosis is achieved, because
this was the most signiﬁcant predictor of ulcer healing.
UGS of IPVs is a safe treatment, with few complica-
tions and an easy ability to retreat in the setting of initial
failure of thrombosis. After polidocanol was approved by
the Food and Drug Administration as a sclerosant, we
changed from STS due to evidence indicating polidocanol
may have a better safety protocol, be as or more effective
than STS, and be better tolerated.34 Our incidence of
DVT was low and comparable with other known
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ablation include ecchymosis, induration, and pain, whereas
paresthesias, hyperpigmentation, and phlebitis occur in the
minority of patients.27,38,39 Multiple needle punctures dur-
ing sclerotherapy can lead to vasospasm or hematoma, but
in our population, the common side effects seen during
sclerotherapy were minimal. Patients tolerated sclerother-
apy much more comfortably than ablation therapy and
often recovered faster.40,41 Thrombosis of IPVs was the
most powerful predictor of venous ulcer healing, and ulcer
healing was achieved in >50% of patients. These patients
had suffered with venous stasis wound(s) for years and
had few remaining therapeutic options. A large initial ulcer
area, however, predictably demonstrated a lower chance
that an ulcer would ultimately heal, even with successful
perforator thrombosis.
Healing status of ulcers was determined at an arbitrarily
deﬁned study end period, and thus, recurrence of venous
ulcers incorporates the time-dependent nature of the dis-
ease. Our data demonstrate recurrence of ulcers was signif-
icantly predicted by length of follow-up, a ﬁnding that is
consistent with the natural history of venous ulceration
and represents a selection bias, in that patients who heal
are less likely to return to the clinic, even when promp-
ted.42 Increased ulceration with long-term follow-up also
speaks to the nature of new IPVs appearing in the at-risk
areas or the occurrence of late recanalizations. Unfortu-
nately, our largely retrospective review did not provide
adequate data on the exact perforator locations to enable
accurate reporting of whether new injections a signiﬁcant
time after demonstrated thrombosis represented de novo
perforators vs recanalization. We did ﬁnd that continued
therapy and repeat injections with IPV thrombosis led to
healing. Thus, improving comorbidities, such as hyperten-
sion, continued use of compressive therapy, and aggressive
surveillance and perforator ablation may all contribute to
maintenance of ulcer healing.
This study has a number of limitations. The most
important is the largely retrospective nature of the review.
Variances in long-term follow-up have prohibited stan-
dardized healing curves. Our small sample size, combined
with high variance in initial ulcer sizes and heterogeneity
in recurrence rates, precluded a cumulative analysis of heal-
ing rates of all ulcers.
Owing to the inconsistency of quality of life data being
collected on patients, it was not valuable in our current
analysis. Similarly, it was not possible to control for wound
care methods. Ointments and exact methods of compres-
sion, for example, Unna boot vs short stretch bandages,
often changed according to patient preferences, ability to
comply with the prescribed regimen, and perceived success
of the current therapy. In addition, although detailed
documentation of perforator location was recorded during
initial ultrasound evaluation and foam injection, variability
in ultrasound sonographers may make follow-up compari-
son difﬁcult in determining whether a suspected perforator
recurrence was newly formed or indeed recanalized.CONCLUSIONS
Ultrasound-guided injection of reﬂuxing perforator
veins in CEAP 6 patients was found to be safe and to pre-
dict ulcer healing. Thrombosis of pathologic perforators
was the most powerful predictor of ulcer healing in our
analysis. Perforator closure may require multiple injections
but is associated with low complication rates. Foam sclero-
therapy, or other methods of perforator closure, is there-
fore recommended for treatment of nonhealing venous
ulcers.
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Submitted Aug 2, 2013; accepted Nov 13, 2013.DISCUSSIONDr Albeir Mousa (Charleston, WVa). I have two questions.
The ﬁrst, what size perforator you have treated, and how far
from the ulcer location that can still contribute ulcer pathology?
Dr Ellen Dillavou. We follow the Society for Vascular Sur-
gery (SVS) guidelines for pathologic perforators; so, a perforator
of $3.5 mm is considered pathologic and so we will inject any-
thing of that size or larger.
Dr Mousa. So about two-thirds of your cohort was resistant
to treatment. And I notice you keep following them. Did you eval-
uate the central venous system, iliac vein, like any venous outﬂow
study to delineate this issue?
Dr Dillavou. Yes, we perform complete duplexes of all of our
patients initially and then as clinically indicated. So, if we per-
formed our intervention and the ulcer heals, we continue thatcourse. However, if there is a stagnation in healing, we go back
and perform a new duplex ultrasound. If there is any suggestion
of venous outﬂow obstruction, such as with chronic DVT or
dampened femoral waveforms on ultrasound, we would then
perform a central venous study.
Dr Nicos Labropoulos (Stony Brook, NY). That was a great
talk. I think this is real-world data, and this is what you expect
to see in the population you are presenting. However, it is a bit
misleading to indicate that the treatment of the perforators by
the foam is what is causing the ulcers to heal. I believe that the
foam does the job by closing all the reﬂuxing tributaries and partic-
ularly the microvascular tree, which is actually responsible for the
development of the ulcer. And in your population in particular it
is evident, because only one-third of your patients had deep vein
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1376 Kiguchi et al May 2014disease. So it is clear that the foam was successful to that extent
because you were able to treat a signiﬁcant number of veins within
and around the ulcer.
Dr Dillavou. I completely agree, and one advantage of foam
is that it does treat the network of varicosities. I think this is one
tool. Dr Lawrence has elegantly demonstrated that ablation of per-
forators also increases ulcer healing, so the foam perforator abla-
tion has value. This is just one part of the ulcer treatment package.
Dr Kathleen Gibson (Bellevue, Wash). The question I had,
and I might have missed in your talk, what was your compression
regimen after treatment? Did you track patient compliance? And if
so, did that have any effect on either ulcer healing or the success of
thrombosis of the perforator, or do you think that that is an impor-
tant piece in the healing and in the success of your procedure?
Dr Dillavou. Our standard regimen is to put patients in a
compressive stretch wrap for 24 hours after foam sclerotherapy.
Or if they are in an Unna boot, we put the Unna boot on imme-
diately after the treatment and leave that on for 3 days, or a week,
however long the patient leaves the Unna boot on.
I do think it is important, and in general our patient popula-
tion was very compliant with compression. Unfortunately, the
largely retrospective nature of this study didn’t allow us to control
for each type of compression, and there was a lot of bouncing back
and forth with patients between different types of Unna boots and
short stretch bandages, et cetera. But they were all in high-grade
compression. We are very aggressive with that and, by and large,
the patients are compliant.
Dr Gregory Moneta (Portland, Ore). I have a question about
the status of the patients prior to when you began treating them.
You said that they were all under maximum medical management.
Were these patients de novo patients when they presented to you?
If not, and if they were under your continuous management, why
do you wait 2 years to treat them?
Dr Dillavou.We get a large number of patients referred from
other institutions. And the reason it was only 2 years of compres-
sive therapy prior to intervention for many patients is because
although they would report a history of many years of ulcer,they were not under our care at that time. And so we started
tracking the study from when we knew they were getting adequate
compression and medical therapy. Much of the medical and
compressive therapy was done in our clinics.
This study also reﬂects a change in our practice patterns:
becoming more aggressive with elimination of reﬂuxing perfora-
tors and correction of outﬂow obstruction, and that has happened
over the last few years. Prior to the mid-2000s we were less aggres-
sive in our practice and had a large number of patients who were
treated with compression only.
Dr Alan Dietzek (Danbury, Conn). I was curious, how did
you select your sclerosant regimen for these patients? Do you
use a higher concentration if you don’t get a thrombosis of the
perforator the ﬁrst time? Did you see a difference when you
switched to polidocanol from Sotradecol (AngioDynamics,
Latham, NY)? And have you considered the combined use of
foam sclerotherapy and heat ablation for those perforators that
don’t thrombose with sclerotherapy only?
Dr Dillavou. We switched from Sotradecol to polidocanol as
a group. We made a total change in our practice in May 2010
because we felt that polidocanol was safer and better tolerated
than Sotradecol. We did not see a difference in thrombosis rates
or complications between Sotradecol and polidocanol. Initially
we were using 3% polidocanol for all ultrasound-guided perforator
injections because we felt that that would be more effective. But
then after the Varisolve trial (BTG International Inc, West Con-
shohocken, Pa) results showed that there was not a signiﬁcant dif-
ference between 1% and 3%, we then downgraded to 1% and we
have not seen a difference in our thrombosis rates or complica-
tions. And so now 1% polidocanol is the standard that we use.
Based on these results, we have become more aggressive with
heat ablation of perforators. So anyone with a 5-mm perforator,
the obese men on Coumadin (Bristol-Myers Squibb, Princeton,
NJ), and those who fail ultrasound-guided injection, all get a
heat ablation, and those we are doing as a combined heat ablation
and chemical ablation at the same time hopefully through the same
access site.
